Navigation Links
Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
Date:9/9/2013

y significantly enhanced the development of our spinal muscular atrophy and myotonic dystrophy programs," said B. Lynne Parshall, chief operating officer at Isis Pharmaceuticals.

The collaboration announced today follows three previous collaborations between Biogen Idec and Isis. In the first half of 2012, Isis and Biogen Idec established collaborations to develop antisense drugs to treat spinal muscular atrophy and myotonic dystrophy type 1. Later that same year, Isis and Biogen Idec entered into a third collaboration to discover and develop antisense drugs against three novel targets for neurological disorders.

Isis Conference Call
At 11:30 a.m. Eastern Time Monday, Sept. 9, 2013, Isis will conduct a live webcast conference call to discuss its new strategic collaboration. Interested parties may listen to the call by dialing 866-652-5200, or access the webcast at www.isispharm.com. A webcast replay will be available for a limited time at the same address.

About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the Company generates more than $5 billion in annual revenues. For product labeling, press releases and additional information about the Company, please visit www.biogenidec.com.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 30 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metaboli
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Biogen Idec
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
2. Isis Pharmaceuticals Earns $3.5 Million from Biogen Idec
3. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
4. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
5. BioGenex and Abbott Molecular Conclude Successful Partnership
6. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
7. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
8. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
9. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
10. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
11. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN ANTONIO , Jan. 15, 2014 Most ... take, according to a recent online survey* sponsored by ... among the National Osteoporosis Foundation online support community, ... to take medication that comes in a form other ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... , MOUNTAIN VIEW, Calif. , Jan. ... of a Phase I clinical trial of CCX168, an ... is a highly potent and very selective compound that ... the body,s complement system and a potent driver of ...
... , EXTON, Pa. , Jan. 28 ... medical technology company that provides innovative solutions and technologies for a ... three and six months ended December 31, 2009 . All ... to those provided in the Company,s January 15, 2010 ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 2Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 3Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 4Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 5Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 6Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 7Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 8Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 9Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 10Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 11Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 12Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 13Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 14Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 15Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 16Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 17Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 18Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 19Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results 20
(Date:4/24/2014)... the influenza pH1N1 virus caused the first flu pandemic ... May 2009 and killed more than 50 people in ... mainly during flu epidemics (winter/spring seasons). , Infections ... complicated illnesses. World Health Organization has recommended Tamiflu for ... disadvantage of this drug is that it targets viral ...
(Date:4/23/2014)... Using frozen stool from healthy, unrelated donors was ... relapsing diarrhea caused by Clostridium difficile , ... Clinical Infectious Diseases and available online. ... equally effective whether given via a colonoscope or ... may make this promising treatment more readily available ...
(Date:4/23/2014)... University Spokane have developed a new way to ... behind the wheel. , Their recently patented technology ... variable in drowsy driversand offers an affordable and ... drowsiness detection systems. , Van Dongen"Video-based systems that ... drifting out of its lane are cumbersome and ...
(Date:4/23/2014)... Society for Radiation Oncology (ASTRO) has issued a ... for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that ... the treatment of endometrial cancer. The guideline,s executive ... of Practical Radiation Oncology (PRO), the ... guideline is available as an open-access article online ...
(Date:4/23/2014)... pathway that helps prevent new cells from receiving too ... been directly linked to cancer and other diseases. , ... the end of cell division, the enzyme Cdc14 activates ... are fully repaired before the parent cell distributes copies ... safeguard against some of the most devastating genome errors, ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:WSU innovation improves drowsy driver detection 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... , THURSDAY, Aug. 25 (HealthDay News) -- Alzheimer,s disease is ... the announcement by celebrated women,s basketball coach Pat Summit of ... on the less common, but perhaps even more devastating, form ... United States, or about 5 percent of those with Alzheimer,s, ...
... (HealthDay News) -- Your immune system response to a flu ... that immune reaction can be observed through gene activity, according ... genes in 267 blood samples from 17 healthy volunteers who ... complex differences in the immune responses between the half of ...
... Reinberg HealthDay Reporter , THURSDAY, Aug. 25 ... higher odds of dying if they,re admitted over the ... finds equally good results for patients treated at comprehensive ... so-called "weekend effect" -- an increased risk of death ...
... University researchers have successfully re-engineered the protein-making machinery in ... revolutionize the study and treatment of a variety of ... E. coli , which allows us synthesize special ... states," said Jesse Rinehart of the Department of Cellular ...
... Providing access to an outpatient clinic isn,t enough to keep ... from returning to the emergency department (ED) for follow-up care, ... dressing changes, according to new Johns Hopkins research. Reporting ... say that patients with Medicaid, Medicare and those with no ...
... Thomas Jefferson University , among other institutions, including ... developed single vaccines to protest against both rabies and ... bivalent vaccines have several advantages over other Ebola candidates ... humans and primates. It,s built on the same platform ...
Cached Medicine News:Health News:Coach Summitt's Diagnosis Puts Spotlight on Early-Onset Alzheimer's 2Health News:Coach Summitt's Diagnosis Puts Spotlight on Early-Onset Alzheimer's 3Health News:Coach Summitt's Diagnosis Puts Spotlight on Early-Onset Alzheimer's 4Health News:Specialized Stroke Centers Deliver on the Weekends 2Health News:Specialized Stroke Centers Deliver on the Weekends 3Health News:Yale researchers use genetic code to engineer a living protein 2Health News:Uninsured trauma patients are more likely to use the ED for follow-up care 2Health News:Uninsured trauma patients are more likely to use the ED for follow-up care 3Health News:Single vaccines to protect against both rabies and Ebola 2
RapidStrep A test is a qualitative test that detects group A,streptococcal antigen. The test is a rapid, in vitro assay. It is,intended for professional use to help diagnose Strep A,infection i...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
Inquire...
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
Medicine Products: